- Home
- APM vs BDRX Comparison
APM vs BDRX Comparison
Compare APM & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- BDRX
- Stock Information
- Founded
- APM 2010
- BDRX 2000
- Country
- APM United Kingdom
- BDRX United Kingdom
- Employees
- APM N/A
- BDRX N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- BDRX Health Care
- Exchange
- APM Nasdaq
- BDRX Nasdaq
- Market Cap
- APM 6.1M
- BDRX 5.8M
- IPO Year
- APM 2018
- BDRX N/A
- Fundamental
- Price
- APM $0.99
- BDRX $0.90
- Analyst Decision
- APM
- BDRX
- Analyst Count
- APM 0
- BDRX 0
- Target Price
- APM N/A
- BDRX N/A
- AVG Volume (30 Days)
- APM 92.1K
- BDRX 3.2M
- Earning Date
- APM 07-07-2025
- BDRX 04-11-2025
- Dividend Yield
- APM N/A
- BDRX N/A
- EPS Growth
- APM N/A
- BDRX N/A
- EPS
- APM N/A
- BDRX N/A
- Revenue
- APM N/A
- BDRX N/A
- Revenue This Year
- APM N/A
- BDRX N/A
- Revenue Next Year
- APM N/A
- BDRX N/A
- P/E Ratio
- APM N/A
- BDRX N/A
- Revenue Growth
- APM N/A
- BDRX N/A
- 52 Week Low
- APM $0.46
- BDRX $0.78
- 52 Week High
- APM $7.49
- BDRX $41.50
- Technical
- Relative Strength Index (RSI)
- APM 47.58
- BDRX 39.25
- Support Level
- APM $1.01
- BDRX $0.85
- Resistance Level
- APM $1.06
- BDRX $0.97
- Average True Range (ATR)
- APM 0.10
- BDRX 0.11
- MACD
- APM -0.02
- BDRX -0.00
- Stochastic Oscillator
- APM 15.68
- BDRX 28.24
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.